With Aduhelm in tatters, the search is on for Michel Vounatsos' replacement at Biogen; David Liu, Roger Perlmutter join insitro's SAB
→ Because of the dearth of Alzheimer’s treatments, Biogen pushed aggressively to cross the regulatory goal line with aducanumab despite early trial wrap-ups and pervasive …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
